Title: A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura. Author: Kjaersgaard M, Hasle H. Journal: Pediatr Blood Cancer; 2006 Oct 15; 47(5 Suppl):717-20. PubMed ID: 16933265. Abstract: Treatment of childhood idiopathic thrombocytopenic purpura is still an area of controversy. We reviewed the literature on anti-D treatment. Most studies used intravenous anti-D. Single doses of 50 microg/kg increased the platelet count to >or=20x10(9)/L in 70% of the children within 3 days. Intravenous anti-D seems safe in classic childhood ITP although hemolysis and occasionally renal failure may be of concern. A few studies reported intramuscularly or subcutaneously administered anti-D. Further studies on the optimal dose and route of administration of anti-D are warranted.[Abstract] [Full Text] [Related] [New Search]
